$SPRB News

HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150

Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $150

SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q1 EPS $(8.94) Misses $(8.78) Estimate

Craig-Hallum Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $140

Spruce Biosciences shares are trading lower after the company announced the pricing of its $60 million offering of 1.15 million shares and pre-funded warrants at $50 per share.

Spruce Biosciences shares are trading lower after the company announced the pricing of its $60 million offering of 1.15 million shares and pre-funded warrants at $50 per share.

Why Is Spruce Biosciences Stock Sinking Tuesday?

Reported Earlier, Spruce Biosciences Prices Public Offering Of 1.15M Shares And Pre-Funded Warrants At $50.00 Per Share, Raising $60M Gross Proceeds

Spruce Biosciences shares are trading lower after the company announced a public offering.

Spruce Biosciences Commences Proposed Public Offering; Terms Not Disclosed

Spruce Biosciences Says On March 16, Entered Termination Agreement With Kaken Pharmaceutical; Collaboration Agreement With Kaken Pharmaceutical To Terminate Effective March 31, 2026; All Licenses & Rights Granted By Co To Kaken To Be Terminated; No Unearned Milestone Payments Or Royalties

Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $170

HC Wainwright & Co. Reiterates Buy on Spruce Biosciences, Maintains $200 Price Target

Spruce Biosciences shares are trading higher. The company reported its Q4 financial results.

SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q4 EPS $(36.25) Misses $(4.22) Estimate

Spruce Biosciences 2025 Net Loss Shrinks To $39M Vs $53M In 2024, Zero Revenue Against Prior Year's $4.9M; Eyes Q4 2026 BLA Submission For TA-ERT While Securing $50M Avenue Capital Loan Facility

HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $200

Spruce Biosciences Completes Type B Meetings With FDA Regarding Its Upcoming Biologics License Application Submission For Tralesinidase Alfa Enzyme Replacement Therapy, Application Submission Now Anticipated In Q4 For Sanfilippo Syndrome Type B

Reported Sunday, Harbour BioMed Strengthens Strategic Collaboration With Spruce Biosciences Through Common Stock Acquisition

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration